Significant variations exist when comparing cancer care systems in the United States and Western Europe. The American model, generally characterized by for-profit insurance and a emphasis on innovation, often leads to early adoption of cutting-edge therapies, albeit at a significantly greater cost. On the other hand, Continental systems frequently